<DOC>
	<DOCNO>NCT00795275</DOCNO>
	<brief_summary>Regulation endogenous glucose production ( EGP ) insulin secretion major action glucagon-like peptide-1 ( GLP-1 ) . Determining whether alteration GLP-1 may contribute abnormal EGP insulin secretion people impair fast glucose ( IFG ) objective current study . The investigator hypothesize defect GLP-1 may explain inappropriate basal EGP diminish insulin secretion IFG , , furthermore , increase circulate GLP-1 level ( use new medicine call `` sitagliptin '' ) investigator could reverse defect .</brief_summary>
	<brief_title>Incretin Effect People With Impaired Fasting Glucose</brief_title>
	<detailed_description />
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Healthy , sedentary , nonsmoker , men woman 4570 year old Subjects place 1 2 group base two 2hour 75g oral glucose tolerance test ( 2h OGTT ) , separate one week : control group normal glucose tolerance ( NGT ; n=14 ; fast glucose &lt; 5.6 mmol/l 2h OGTT &lt; 7.8 mmol/l ) , IFG ( n=10 ; fast glucose 5.66.9 mmol/l , 2h OGTT &lt; 7.8 mmol/l ) . Subjects exclude : thyroid stimulate hormone &lt; 50 &gt; 500 mU/l , fast triglyceride &gt; 10.3 mmol/l , creatinine &gt; 130 Î¼mol/l , elevate liver function test ( &gt; 2X normal ) , hematocrit &lt; 38 % , WBC &lt; 3.0 x 103 . Use medication lipid and/or glucose lowering also exclude enrollee . Women may use hormone replacement therapy past 1 year . Smokers . BMI &lt; 25 &gt; 40 kg/m2 . Diabetes impaired glucose tolerance .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>pre-diabetes</keyword>
	<keyword>isotope</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>insulin action</keyword>
	<keyword>GLP-1</keyword>
	<keyword>simple obesity</keyword>
	<keyword>impaired fasting glucose</keyword>
</DOC>